| Website | txcell.com |
| Category | BioTech |
| Phone | +33(0) 497 218 300 |
| contact@txcell.com | |
| Employees |
| TOTAL | $16.1M |
| FUNDING TOTAL | $16.1M |
| Series C, 11/12 InnoBio Fund Auriga Partners Seventure Partners | €12.4M |
TxCell, a spin off of Inserm (France’s National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn’s disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.
